Alan B. Sandler
CIK 1835966 · View on SEC EDGAR ↗
First SEC filing: March 26, 2026 · Latest: March 26, 2026
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Jan. 20, 2026 | ALXO | A | 10,100 | — | — | 10,100 Direct | — | Acquired | (price as of 2026-08-20) |
| June 25, 2022 | ZLAB | A | 73,000 | — | — | 73,000 Direct | — | Acquired | (price as of 2026-08-20) |
| April 1, 2022 | ZLAB | M | 1,060 | — | — | 4,240 Direct | -20.00% | Disposed | (price as of 2026-08-20) |
| April 1, 2022 | ZLAB | A | 16,692 | — | — | 16,692 Direct | — | Acquired | (price as of 2026-08-20) |
| April 1, 2022 | ZLAB | A | 87,699 | — | — | 87,699 Direct | — | Acquired | (price as of 2026-08-20) |
| April 1, 2022 | ZLAB | M | 1,060 | — | — | 28,985 Direct | +3.80% | Acquired | (price as of 2026-08-20) |
| April 1, 2021 | ZLAB | A | 5,300 | — | — | 5,300 Direct | — | Acquired | (price as of 2026-08-20) |
| April 1, 2021 | ZLAB | A | 28,000 | — | — | 28,000 Direct | — | Acquired | (price as of 2026-08-20) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Jan. 20, 2026 | ALXO | Stock option (right to buy) | Common Stock (10,100) | $1.32 | Jan. 19, 2036 | 10,100 | Acquired |
| June 25, 2022 | ZLAB | Restricted Share Units | American Depositary Shares (73,000) | — | — | 73,000 | Acquired |
| April 1, 2022 | ZLAB | Restricted Share Units | American Depositary Shares [F1] (1,060) | — | — | 1,060 | Disposed |
| April 1, 2022 | ZLAB | Restricted Share Units | American Depositary Shares [F1] (16,692) | — | — | 16,692 | Acquired |
| April 1, 2022 | ZLAB | Stock Options (Right to Buy) | American Depositary Shares [F1] (87,699) | $45.47 | April 1, 2032 | 87,699 | Acquired |
| April 1, 2021 | ZLAB | Restricted Share Units | Ordinary Shares (5,300) | — | — | 5,300 | Acquired |
| April 1, 2021 | ZLAB | Stock Options (Right to Buy) | Ordinary Shares (28,000) | $130.96 | April 1, 2031 | 28,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 5 holdings
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| March 26, 2026 | RVMDW | Common Stock | 53,000 | Direct |
| March 26, 2026 | RVMDW | Stock Option (Right to Buy)→ Common Stock (167,300) | 167,300 | Direct |
| March 26, 2026 | RVMDW | Stock Option (Right to Buy)→ Common Stock (11,700) | 11,700 | Direct |
| Jan. 4, 2021 | ZLAB | Ordinary Shares | 30,000 | Direct |
| Jan. 4, 2021 | ZLAB | Stock Option (Right to Buy)→ Ordinary Shares (47,000) | 47,000 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
ZLAB
President, Head of Global Development, Oncology| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2021 | $540,000 | $300,000 | $3,194,047 | — | $345,600 | — | $6,708 | $6,622,039 |
| 2020 | $45,000 | $500,000 | $3,267,900 | — | — | — | — | $7,063,890 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.